SCHEMBL3025210

SCHEMBL3025210

C[C@@H](CNc1nc2ccccc2s1)NC(=O)[C@@H](N)CC1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
GAA P10253 3/20 0.48
ALDH1A1 P00352 4/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CNR1 P21554 1/20 0.45
MAPK1 P28482 2/20 0.44
HPGD P15428 1/20 0.44
CSNK1D P48730 1/20 0.42
POLB P06746 1/20 0.41
CTSL P07711 2/20 0.41
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8291062 0.81 CTSS (0.59) NPC1RAB9ASMN1; SMN2CTSLCTSS
SCHEMBL3835476 0.79 CTSS (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL3026025 0.78 CTSS (0.51) CTSLCTSSCTSKPCSK9
SCHEMBL4799916 0.75 TAS1R3 (0.49) NPC1RAB9ACTSLCTSSCTSK
SCHEMBL4796447 0.75 KMT2A (0.43) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL3025207 0.75 NPC1 (0.51) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4799977 0.74 TP53 (0.46) CTSLCTSSCTSKTP53
SCHEMBL6491120 0.74 METAP2 (0.59) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4801927 0.74 CTSS (0.41) CTSLCTSSCTSK
SCHEMBL4797862 0.73 CTSS (0.48) CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658267-B1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2009-10-14 EP claimed
US-7314872-B2 Inhibitors of cathepsin S IRM LLC (BM) 2008-01-01 US claimed
US-20050113356-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-05-26 US claimed
US-20100204200-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2010-08-12 US disclosed
US-7732449-B2 Inhibitors of cathepsin S IRM LLC (BM) 2010-06-08 US disclosed
EP-1658267-B1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2009-10-14 EP disclosed
US-20090137570-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2009-05-28 US disclosed
US-7501408-B2 Inhibitors of cathepsin S IRM LLC (BM) 2009-03-10 US disclosed
US-20080108595-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2008-05-08 US disclosed
US-7314872-B2 Inhibitors of cathepsin S IRM LLC (BM) 2008-01-01 US disclosed
US-20050113356-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137570-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ NPC1 82/4885RAB9A 905/4885SMN1; SMN2 2505/4885
US-20080108595-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ NPC1 82/4885RAB9A 905/4885SMN1; SMN2 2505/4885
US-20050113356-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ NPC1 82/4885RAB9A 905/4885SMN1; SMN2 2505/4885
US-20100204200-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSE, CTSV NPC1 221/4885RAB9A 330/4885SMN1; SMN2 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.